These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 35381275)

  • 41. Phase II study of the American Brachytherapy Society guidelines for the use of high-dose rate brachytherapy in the treatment of cervical carcinoma: is 45-50.4 Gy radiochemotherapy plus 31.8 Gy in six fractions high-dose rate brachytherapy tolerable?
    Shakespeare TP; Lim KH; Lee KM; Back MF; Mukherjee R; Lu JD;
    Int J Gynecol Cancer; 2006; 16(1):277-82. PubMed ID: 16445645
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Role of brachytherapy in the boost management of anal carcinoma with node involvement (CORS-03 study).
    Moureau-Zabotto L; Ortholan C; Hannoun-Levi JM; Teissier E; Cowen D; Salem N; Lemanski C; Ellis S; Resbeut M
    Int J Radiat Oncol Biol Phys; 2013 Mar; 85(3):e135-42. PubMed ID: 23195780
    [TBL] [Abstract][Full Text] [Related]  

  • 43. High-dose-rate interstitial brachytherapy in recurrent and previously irradiated head and neck cancers--preliminary results.
    Narayana A; Cohen GN; Zaider M; Chan K; Lee N; Wong RJ; Boyle J; Shaha A; Kraus D; Shah J; Zelefsky MJ
    Brachytherapy; 2007; 6(2):157-63. PubMed ID: 17434110
    [TBL] [Abstract][Full Text] [Related]  

  • 44. High dose rate versus low dose rate intracavity brachytherapy for locally advanced uterine cervix cancer.
    Wang X; Liu R; Ma B; Yang K; Tian J; Jiang L; Bai ZG; Hao XY; Wang J; Li J; Sun SL; Yin H
    Cochrane Database Syst Rev; 2010 Jul; (7):CD007563. PubMed ID: 20614461
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Brachytherapy improves biochemical failure-free survival in low- and intermediate-risk prostate cancer compared with conventionally fractionated external beam radiation therapy: a propensity score matched analysis.
    Smith GD; Pickles T; Crook J; Martin AG; Vigneault E; Cury FL; Morris J; Catton C; Lukka H; Warner A; Yang Y; Rodrigues G
    Int J Radiat Oncol Biol Phys; 2015 Mar; 91(3):505-16. PubMed ID: 25596107
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Propensity score-matched analysis comparing dose-escalated intensity-modulated radiation therapy versus external beam radiation therapy plus high-dose-rate brachytherapy for localized prostate cancer.
    Tamihardja J; Lawrenz I; Lutyj P; Weick S; Guckenberger M; Polat B; Flentje M
    Strahlenther Onkol; 2022 Aug; 198(8):735-743. PubMed ID: 35551434
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Long term results of a prospective dose escalation phase-II trial: interstitial pulsed-dose-rate brachytherapy as boost for intermediate- and high-risk prostate cancer.
    Lettmaier S; Lotter M; Kreppner S; Strnad A; Fietkau R; Strnad V
    Radiother Oncol; 2012 Aug; 104(2):181-6. PubMed ID: 22853851
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Adjuvant electronic brachytherapy for endometrial carcinoma: A 4-year outcomes report.
    Sarria GR; Sperk E; Wenz F; Schneider F; Abo-Madyan Y; Giordano FA; Ehmann M
    Brachytherapy; 2020; 19(5):635-641. PubMed ID: 32651094
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The 15-year outcomes of high-dose-rate brachytherapy for radical dose escalation in patients with prostate cancer - a benchmark for high-tech external beam radiotherapy alone?
    Galalae RM; Zakikhany NH; Geiger F; Siebert FA; Bockelmann G; Schultze J; Kimmig B
    Brachytherapy; 2014; 13(2):117-22. PubMed ID: 24360880
    [TBL] [Abstract][Full Text] [Related]  

  • 50. High-dose-rate brachytherapy boost for prostate cancer: Comparison of three different fractionation schemes.
    Falk AT; Demontoy S; Chamorey E; Chand ME; Gautier M; Azria D; Zaki S; Chevallier D; Cham Kee DL; Hannoun-Lévi JM
    Brachytherapy; 2017; 16(5):993-999. PubMed ID: 28754301
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Conservative treatment of anal canal carcinoma with external radiotherapy and interstitial brachytherapy, with or without chemotherapy: long-term results].
    Berger C; Félix-Faure C; Chauvet B; Vincent P; Alfonsi M; Coudurier P; Plat F; Reboul F
    Cancer Radiother; 1999; 3(6):461-7. PubMed ID: 10630158
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Rates of rectal toxicity in patients treated with high dose rate brachytherapy as monotherapy compared to dose-escalated external beam radiation therapy for localized prostate cancer.
    Parzen JS; Ye H; Gustafson G; Yan D; Martinez A; Chen PY; Ghilezan M; Sebastian E; Limbacher A; Krauss DJ
    Radiother Oncol; 2020 Jun; 147():123-129. PubMed ID: 32276193
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Combination external beam radiotherapy and high-dose-rate intracavitary brachytherapy for uterine cervical cancer: analysis of dose and fractionation schedule.
    Toita T; Kakinohana Y; Ogawa K; Adachi G; Moromizato H; Nagai Y; Maehama T; Sakumoto K; Kanazawa K; Murayama S
    Int J Radiat Oncol Biol Phys; 2003 Aug; 56(5):1344-53. PubMed ID: 12873679
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Treatment results of high-dose-rate remote afterloading brachytherapy for cervical cancer and retrospective comparison of two regimens.
    Wong FC; Tung SY; Leung TW; Sze WK; Wong VY; Lui CM; Yuen KK; O SK
    Int J Radiat Oncol Biol Phys; 2003 Apr; 55(5):1254-64. PubMed ID: 12654435
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Short-term Toxicity of High Dose Rate Brachytherapy in Prostate Cancer Patients with Inflammatory Bowel Disease.
    Mohammed W; Hoskin P; Henry A; Gomez-Iturriaga A; Robinson A; Nikapota A
    Clin Oncol (R Coll Radiol); 2018 Sep; 30(9):534-538. PubMed ID: 30099986
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Predictive factors for response and toxicity after brachytherapy for rectal cancer; results from the HERBERT study.
    Rijkmans EC; Marijnen CAM; van Triest B; Ketelaars M; Cats A; Inderson A; van den Ende RPJ; Laman MS; Kerkhof EM; Nout RA
    Radiother Oncol; 2019 Apr; 133():176-182. PubMed ID: 30935576
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Two decades of high dose rate brachytherapy with external beam radiotherapy for prostate cancer.
    Åström L; Grusell E; Sandin F; Turesson I; Holmberg L
    Radiother Oncol; 2018 Apr; 127(1):81-87. PubMed ID: 29496280
    [TBL] [Abstract][Full Text] [Related]  

  • 58. High-dose-rate brachytherapy and external-beam radiotherapy for hormone-naïve low- and intermediate-risk prostate cancer: a 7-year experience.
    Aluwini S; van Rooij PH; Kirkels WJ; Jansen PP; Praag JO; Bangma CH; Kolkman-Deurloo IK
    Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):1480-5. PubMed ID: 22285661
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Ten-year survival after High-Dose-Rate Brachytherapy combined with External Beam Radiation Therapy in high-risk prostate cancer: A comparison with the Norwegian SPCG-7 cohort.
    Wedde TB; Småstuen MC; Brabrand S; Fosså SD; Kaasa S; Tafjord G; Russnes KM; Hellebust TP; Lilleby W
    Radiother Oncol; 2019 Mar; 132():211-217. PubMed ID: 30389241
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prostate preservation by combined external beam and HDR brachytherapy in nodal negative prostate cancer.
    Kovács G; Galalae R; Loch T; Bertermann H; Kohr P; Schneider R; Kimming B
    Strahlenther Onkol; 1999 Jun; 175 Suppl 2():87-8. PubMed ID: 10394408
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.